Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
The Annual General Meeting 2023 of Scandion Oncology A/S (the "Company") was held on 26 April 2023 at 2:00 p.m.
All proposals were adopted in accordance with the notice.
After the general meeting, the board of directors constituted itself with Martin Møller as chairman and Jørgen Bardenfleth as deputy chairman.
The full minutes of the annual general meeting are attached to this notice.
The agenda of the annual general meeting was as follows:
| Election of chairman of the meeting |
| Report from the board of directors on the Company's activities in the past year |
| Presentation of the audited annual report for approval |
| Proposal of notice of discharge to the board of directors and the executive board |
| Decision on appropriation of profit or loss as recorded in the approved annual report |
| Proposal of approval of the board of directors' fee for 2023 |
| Election of members of the board of directors |
| Election of auditor |
| Any other business |
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com
The information was provided by the contact person above for publication on 26 April 2023 at 17.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.
